Aspen Neuroscience grants chair 321,672-share award

Although fully vested at grant, share delivery is deferred until the lock-up and insider-trading-policy conditions are met, with settlement due no later than December 31, 2027.

Available on EDGAR 11/09/2026 - 05:10 PM EST Accepted by SEC EDGAR 11/09/2026 - 05:10 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Aspen Neuroscience, Inc. Executive Chair Faheem Hasnain was granted an award representing 321,672 shares on November 5, 2026. The shares were 100% vested upon grant and are to be delivered in one lump sum on the first trading day in calendar 2027 when the lock-up period has expired or terminated and the company’s insider trading policy permits open-market sales, and no later than December 31, 2027. Following the transaction, Hasnain directly held 348,330 common shares; 36,349 additional shares were held indirectly through a family trust.

Insider Trade Summary

Grant/Award: 321,672 shares

Grant/Award 1 txn

Insider Hasnain Faheem

Role Executive Chair

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	321,672	$0.00	$0.00
Holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 348,330 shares (Direct); Common Stock — 36,349 shares (Indirect, By family trust)

Holdings Before and After: Common Stock, 26,658 to 348,330 shares (Direct)

Footnotes (1)

1. F1. Represents the number of shares of common stock, which were 100% vested upon grant, to be delivered upon settlement of restricted stock unit award under the Reporting Person's executive chair offer letter on the designated deferred settlement date. The restricted stock units will be settled in one lump sum on the first trading day during calendar year 2027 as of which (A) the lock-up period applicable under the Reporting Person's lock-up agreement with the underwriters of the Issuer's initial public offering has expired or terminated and (B) the Reporting Person is permitted to sell shares of Common Stock in the open market under the Issuer's insider trading policy, but in all cases no later than December 31, 2027.

Key Figures

Shares represented by restricted stock unit award: 321,672 shares Vesting upon grant: 100% Direct common shares following transaction: 348,330 shares +2 more

5 metrics

Shares represented by restricted stock unit award 321,672 shares Award granted November 5, 2026

Vesting upon grant 100% Restricted stock unit award

Direct common shares following transaction 348,330 shares Faheem Hasnain, November 5, 2026

Indirect common shares 36,349 shares Held through a family trust as of November 5, 2026

Settlement deadline December 31, 2027 Settlement no later than this date

Key Terms

restricted stock unit award, deferred settlement date, lock-up period, insider trading policy

4 terms

restricted stock unit award financial

"settlement of restricted stock unit award"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

deferred settlement date financial

"on the designated deferred settlement date"

lock-up period regulatory

"the lock-up period applicable under the Reporting Person’s lock-up agreement"

A lock-up period is a fixed time after a stock offering during which company insiders and early investors are legally barred from selling their shares. It matters because when that restriction expires a large block of previously locked-up shares can enter the market at once, potentially lowering the stock price or spiking trading volume—like opening a floodgate—so investors monitor these dates to anticipate price moves and manage risk.

insider trading policy regulatory

"permitted to sell shares of Common Stock in the open market under the Issuer’s insider trading policy"

A written set of rules that tells employees, executives and board members what information they may not use to buy or sell a company's stock and when trading is allowed. Think of it as a playbook or house rules that prevent people with secret knowledge from getting an unfair advantage; it matters to investors because it helps protect fair markets, preserves trust in management, and reduces the risk of legal penalties that can hurt a company’s value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did ASPE Executive Chair Faheem Hasnain receive in his award?

Faheem Hasnain was granted an award representing 321,672 shares on November 5, 2026. The shares were 100% vested upon grant and are to be delivered upon later settlement.

When will Faheem Hasnain’s ASPE award settle?

The award is scheduled to settle in one lump sum on the first trading day in calendar 2027 when the lock-up period under the agreement with the underwriters of Aspen Neuroscience’s initial public offering has expired or terminated and the company’s insider trading policy permits Hasnain to sell shares in the open market. Settlement is due no later than December 31, 2027.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hasnain Faheem

(Last) (First) (Middle)

C/O ASPEN NEUROSCIENCE, INC.

10835 ROAD TO THE CURE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aspen Neuroscience, Inc. [ ASPE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chair

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2026		A		321,672(1)	A	$0.00	348,330	D
Common Stock								36,349	I	By family trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares of common stock, which were 100% vested upon grant, to be delivered upon settlement of restricted stock unit award under the Reporting Person's executive chair offer letter on the designated deferred settlement date. The restricted stock units will be settled in one lump sum on the first trading day during calendar year 2027 as of which (A) the lock-up period applicable under the Reporting Person's lock-up agreement with the underwriters of the Issuer's initial public offering has expired or terminated and (B) the Reporting Person is permitted to sell shares of Common Stock in the open market under the Issuer's insider trading policy, but in all cases no later than December 31, 2027.

	/s/ Jeffrey L. Boerneke, as Attorney-in-Fact	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)